,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,100 Campus Drive,Florham Park,NJ,07932,United States,608 441 8120,https://www.cellectar.com,Biotechnology,Healthcare,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.",15,"{'maxAge': 1, 'name': 'Mr. James V. Caruso', 'age': 63, 'title': 'Pres, CEO & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 846475, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.03,2.03,2.03,2.21,2.03,2.03,2.03,2.21,0.0,1.335062,-0.7809188,67381,67381,620085,3743000,3743000,2.03,2.25,3000,1000,21526528,1.25,4.71,1.8812,1.6893,0.0,0.0,USD,18340068,0.0,6807640,9740510,142507,159856,1690761600,1693440000,0.0146,0.051570002,0.33897,8.42,0.0147,-0.19,1672444800,1703980800,1688083200,-31828904,-3.54,-2.83,1:10,1531785600,-0.572,NCM,EQUITY,CLRB,CLRB,"Cellectar Biosciences, Inc.","Cellectar Biosciences, Inc.",1131633000,America/New_York,EDT,-14400000,2.21,25.0,4.0,12.6,12.0,1.6,buy,5,5152972,0.529,-32085000,584496,0.799,0.87,-1.24366,-3.22693,-17611360,-29138328,0.0,0.0,0.0,USD,
1,100 Campus Drive,Florham Park,NJ,07932,United States,608 441 8120,https://www.cellectar.com,Biotechnology,Healthcare,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.",15,"{'maxAge': 1, 'name': 'Mr. Chad J. Kolean CPA, CPA', 'age': 58, 'title': 'VP, CFO & Sec.', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 453224, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.03,2.03,2.03,2.21,2.03,2.03,2.03,2.21,0.0,1.335062,-0.7809188,67381,67381,620085,3743000,3743000,2.03,2.25,3000,1000,21526528,1.25,4.71,1.8812,1.6893,0.0,0.0,USD,18340068,0.0,6807640,9740510,142507,159856,1690761600,1693440000,0.0146,0.051570002,0.33897,8.42,0.0147,-0.19,1672444800,1703980800,1688083200,-31828904,-3.54,-2.83,1:10,1531785600,-0.572,NCM,EQUITY,CLRB,CLRB,"Cellectar Biosciences, Inc.","Cellectar Biosciences, Inc.",1131633000,America/New_York,EDT,-14400000,2.21,25.0,4.0,12.6,12.0,1.6,buy,5,5152972,0.529,-32085000,584496,0.799,0.87,-1.24366,-3.22693,-17611360,-29138328,0.0,0.0,0.0,USD,
2,100 Campus Drive,Florham Park,NJ,07932,United States,608 441 8120,https://www.cellectar.com,Biotechnology,Healthcare,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.",15,"{'maxAge': 1, 'name': 'Mr. Jarrod  Longcor', 'age': 49, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 625320, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.03,2.03,2.03,2.21,2.03,2.03,2.03,2.21,0.0,1.335062,-0.7809188,67381,67381,620085,3743000,3743000,2.03,2.25,3000,1000,21526528,1.25,4.71,1.8812,1.6893,0.0,0.0,USD,18340068,0.0,6807640,9740510,142507,159856,1690761600,1693440000,0.0146,0.051570002,0.33897,8.42,0.0147,-0.19,1672444800,1703980800,1688083200,-31828904,-3.54,-2.83,1:10,1531785600,-0.572,NCM,EQUITY,CLRB,CLRB,"Cellectar Biosciences, Inc.","Cellectar Biosciences, Inc.",1131633000,America/New_York,EDT,-14400000,2.21,25.0,4.0,12.6,12.0,1.6,buy,5,5152972,0.529,-32085000,584496,0.799,0.87,-1.24366,-3.22693,-17611360,-29138328,0.0,0.0,0.0,USD,
3,100 Campus Drive,Florham Park,NJ,07932,United States,608 441 8120,https://www.cellectar.com,Biotechnology,Healthcare,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.",15,"{'maxAge': 1, 'name': 'Mr. Darrell Shane Lea', 'age': 49, 'title': 'Chief Commercial Officer', 'yearBorn': 1973, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.03,2.03,2.03,2.21,2.03,2.03,2.03,2.21,0.0,1.335062,-0.7809188,67381,67381,620085,3743000,3743000,2.03,2.25,3000,1000,21526528,1.25,4.71,1.8812,1.6893,0.0,0.0,USD,18340068,0.0,6807640,9740510,142507,159856,1690761600,1693440000,0.0146,0.051570002,0.33897,8.42,0.0147,-0.19,1672444800,1703980800,1688083200,-31828904,-3.54,-2.83,1:10,1531785600,-0.572,NCM,EQUITY,CLRB,CLRB,"Cellectar Biosciences, Inc.","Cellectar Biosciences, Inc.",1131633000,America/New_York,EDT,-14400000,2.21,25.0,4.0,12.6,12.0,1.6,buy,5,5152972,0.529,-32085000,584496,0.799,0.87,-1.24366,-3.22693,-17611360,-29138328,0.0,0.0,0.0,USD,
4,100 Campus Drive,Florham Park,NJ,07932,United States,608 441 8120,https://www.cellectar.com,Biotechnology,Healthcare,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.",15,"{'maxAge': 1, 'name': 'Dr. Andrei  Shustov M.D.', 'age': 51, 'title': 'Sr. VP of Medical', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.03,2.03,2.03,2.21,2.03,2.03,2.03,2.21,0.0,1.335062,-0.7809188,67381,67381,620085,3743000,3743000,2.03,2.25,3000,1000,21526528,1.25,4.71,1.8812,1.6893,0.0,0.0,USD,18340068,0.0,6807640,9740510,142507,159856,1690761600,1693440000,0.0146,0.051570002,0.33897,8.42,0.0147,-0.19,1672444800,1703980800,1688083200,-31828904,-3.54,-2.83,1:10,1531785600,-0.572,NCM,EQUITY,CLRB,CLRB,"Cellectar Biosciences, Inc.","Cellectar Biosciences, Inc.",1131633000,America/New_York,EDT,-14400000,2.21,25.0,4.0,12.6,12.0,1.6,buy,5,5152972,0.529,-32085000,584496,0.799,0.87,-1.24366,-3.22693,-17611360,-29138328,0.0,0.0,0.0,USD,
